SAS in Patients With Bronchial Carcinoma

NCT ID: NCT02270853

Last Updated: 2016-02-18

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Clinical Phase

NA

Total Enrollment

100 participants

Study Classification

INTERVENTIONAL

Study Start Date

2014-04-30

Study Completion Date

2016-12-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

In this study it will be analyzed how often the sleep apnea syndrome can be observed in patients with newly diagnosed lung cancer with the help of ApneaLink device by ResMed.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Determination of the SAS- frequence in patients with bronchial carcinoma. The patients will be screened at home for 1 night with the ApneaLink device by ResMed. The apneaLink device is a standard screening tool for sleep apnea in clinical practice.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Sleep Apnea Syndrome Bronchial Carcinoma

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NA

Intervention Model

SINGLE_GROUP

Primary Study Purpose

SCREENING

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

sleep apnea screening with ApneaLinkTM

This is the only group in the present study. Patients with bronchial carcinoma (or reasonable suspicion) perform sleep screening with ApneaLinkTM at home or during the hospitalization.

Group Type OTHER

sleep apnea screening with ApneaLinkTM

Intervention Type DEVICE

ApneaLink is sleep-screening tool that objectively identifies patients with sleep apnea

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

sleep apnea screening with ApneaLinkTM

ApneaLink is sleep-screening tool that objectively identifies patients with sleep apnea

Intervention Type DEVICE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Patients with reasonable suspicion of bronchial carcinoma or histologically proven bronchial carcinoma, which has not been medicated until the study entry and
* Patients with sleep apnea who had recently been diagnosed with bronchial carcinoma.

Exclusion Criteria

* Pregnancy
* other already known malignancies or tumors
* Patients with non-invasive artificial respiration due to a chronic respiratory insufficiencies
Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

RWTH Aachen University

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Michael Dreher, Univ.-Prof.

Role: PRINCIPAL_INVESTIGATOR

RWTH Aachen University Hospital

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Medizinische Klinik I Uniklinik RWTH Aachen

Aachen, North Rhine-Westphalia, Germany

Site Status RECRUITING

Krankenhaus Merheim

Cologne, North Rhine-Westphalia, Germany

Site Status RECRUITING

Florence-Nightingale Hospital

Düsseldorf, , Germany

Site Status RECRUITING

Countries

Review the countries where the study has at least one active or historical site.

Germany

Central Contacts

Reach out to these primary contacts for questions about participation or study logistics.

Angela Habier

Role: CONTACT

0492418037429

Facility Contacts

Find local site contact details for specific facilities participating in the trial.

Michael Dreher, Univ.-Prof.

Role: primary

+49 241 80 37127

Tobias Müller, PD Dr. med.

Role: backup

+49 241 80 37127

Hendrik Storre, PD.Dr.

Role: primary

Krüger Stefan, Prof.

Role: primary

0211/ 409 3441

References

Explore related publications, articles, or registry entries linked to this study.

Dreher M, Kruger S, Schulze-Olden S, Keszei A, Storre JH, Woehrle H, Arzt M, Muller T. Sleep-disordered breathing in patients with newly diagnosed lung cancer. BMC Pulm Med. 2018 May 16;18(1):72. doi: 10.1186/s12890-018-0645-1.

Reference Type DERIVED
PMID: 29769049 (View on PubMed)

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

13-136

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

Sleep Apnea and Lung Cancer
NCT03741647 UNKNOWN
Bronchial Mapping (GCC 1635)
NCT02745548 TERMINATED